Motoki Project
本木项目
基本信息
- 批准号:10661655
- 负责人:
- 金额:$ 17.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-10 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAddressAffectBindingBinding SitesBiochemicalBreast Cancer CellBreast Cancer TreatmentCHD4 geneCRISPR/Cas technologyCancer BiologyCarcinomaCause of DeathCell LineCell ReprogrammingCellsCenters of Research ExcellenceChIP-seqChromatinChromatin Remodeling FactorChromatin StructureDNADataDevelopmentDiseaseDoxycyclineEpigenetic ProcessEpithelial CellsEpitheliumGATA3 geneGene ActivationGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGenomicsGoalsGrantHistonesHomeostasisHumanIn VitroKnowledgeMDA MB 231Malignant NeoplasmsMammary NeoplasmsMeasuresMediatingMethodsModelingMusMutateMutationNeoplasm MetastasisNucleosomesNude MiceOutcomePhenotypePlayPositioning AttributeProcessPublic HealthResearchRoleSMARCA4 geneSystemT47DTechniquesTestingTissuesTumor Suppressor ProteinsWomanWorkXenograft Modelaggressive breast canceranticancer researchcancer cellcofactorepigenomicsepithelial to mesenchymal transitiongenome editinggenomic locushuman diseasein vivoinnovationinnovative technologiesinsightknock-downmalignant breast neoplasmmutantnext generation sequencingnovelnovel therapeutic interventionsmall hairpin RNAtranscription factortranscriptome sequencingtumor growthtumor xenograft
项目摘要
PROJECT SUMMARY. PROJECT 5, M.TAKAKU.
Pioneer transcription factors are capable of binding to closed chromatin and inducing its opening to drive cell
reprogramming. The mechanisms of pioneer factors’ actions remain largely unknown. Using a model of
mesenchymal-to-epithelial transition (MET) in human breast cancer cells, we have discovered that a pioneer
factor GATA3 can open chromatin only at a subset of its binding sites. Our central hypothesis is that GATA3
requires appropriate chromatin context to achieve gene activation that are essential for GATA3 mediated cell
reprogramming. The overall objectives in this grant are to identify chromatin structures and GATA3 co-factors
needed for GATA3-driven chromatin opening and cell reprogramming. The central hypothesis will be tested by
pursuing two specific aims: (1) Define the specific chromatin structures required for GATA3 driven MET; and
(2) Identify the roles of GATA3 co-factors for epithelial cancer cell reprogramming. We will use in vitro and in
vivo breast cancer cell systems to address these specific aims. Under the first aim, the doxycycline inducible
GATA3 expression system in MDA-MB-231 cells that we have established will be used to identify the roles of
nucleosome positioning and linker histones (H1.3 and H1.5) during GATA3-mediated MET. Genomic
techniques including ChIP-seq, ATAC-seq, RNA-seq and MNase-seq together with CRISPR-Cas9 genome
editing and shRNA knockdown methods will be utilized. For the second aim, the same inducible GATA3
expression system and a GATA3 mutant T47D cell line (established by our group) will be used to identify the
roles of chromatin remodeling factors BRG1 and CHD4 in the GATA3-mediated MET and the GATA3 mutant
induced epithelial-to-mesenchymal transition (EMT). It is important to understand the roles of GATA3 co-
factors in the GATA3 mutant cell context, because GATA3 was recently identified as one of the most frequently
mutated genes in breast cancer. Under both aims, mouse xenograft tumor model will be used to identify in vivo
roles of chromatin structures and chromatin remodeling factors in tumor growth and metastasis. The proposed
research is innovative in two ways: first, it features novel hypotheses that will advance the fields of
transcription, chromatin and cancer biology, and secondly, there are multiple innovative technologies that are
proposed, most of which the project leader has developed. The proposed research is significant because it is
expected to provide a new framework for understanding the functions of transcription factors, chromatin
remodeling factors, and chromatin structures in cancer cell reprogramming. Ultimately, such knowledge has
the potential to offer development of new therapeutic strategies of breast cancer treatment.
项目摘要。项目5,M. Takaku。
先锋转录因子能够与封闭的染色质结合,并诱导其开放,从而驱动细胞凋亡。
重新编程先驱因子的作用机制在很大程度上仍不清楚。使用一个模型,
人类乳腺癌细胞中的间充质至上皮转变(MET),我们发现了一个先驱
GATA 3因子仅能在其结合位点的一部分打开染色质。我们的核心假设是GATA 3
需要适当的染色质环境来实现GATA 3介导的细胞增殖所必需的基因活化。
重新编程这项资助的总体目标是鉴定染色质结构和GATA 3辅助因子
GATA 3驱动的染色质开放和细胞重编程所需。中心假设将通过以下方式进行检验:
追求两个具体目标:(1)定义GATA 3驱动的MET所需的特定染色质结构;以及
(2)确定GATA 3辅助因子对上皮癌细胞重编程的作用。我们将在体外和体内
体内乳腺癌细胞系统,以解决这些具体的目标。在第一个目标下,多西环素诱导的
我们建立的MDA-MB-231细胞中的GATA 3表达系统将用于鉴定GATA 3在MDA-MB-231细胞中的作用。
核小体定位和接头组蛋白(H1.3和H1.5)在GATA 3介导的MET。基因组
包括ChIP-seq、ATAC-seq、RNA-seq和MNase-seq以及CRISPR-Cas9基因组的技术
将使用编辑和shRNA敲低方法。对于第二个目的,相同的诱导型GATA 3
表达系统和GATA 3突变T47 D细胞系(由我们小组建立)将用于鉴定GATA 3突变T47 D细胞系。
染色质重塑因子BRG 1和CHD 4在GATA 3介导的MET和GATA 3突变体中的作用
诱导上皮细胞向间充质细胞转化(EMT)。重要的是要了解GATA 3的作用,
GATA 3突变细胞背景下的因素,因为GATA 3最近被确定为最常见的
乳腺癌的基因突变在这两个目标下,小鼠异种移植肿瘤模型将用于体内鉴定
染色质结构和染色质重塑因子在肿瘤生长和转移中的作用。拟议
研究在两个方面是创新的:第一,它以新颖的假设为特色,这些假设将推动以下领域的发展:
转录,染色质和癌症生物学,其次,有多种创新技术,
其中大部分是项目负责人开发的。这项研究之所以重要,是因为
有望为理解转录因子、染色质和蛋白质的功能提供新的框架。
重塑因子和癌细胞重编程中的染色质结构。最终,这些知识
为乳腺癌治疗提供新的治疗策略的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Motoki Takaku其他文献
Motoki Takaku的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Motoki Takaku', 18)}}的其他基金
Role of nucleosome architecture in cellular reprogramming
核小体结构在细胞重编程中的作用
- 批准号:
10567857 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 17.44万 - 项目类别:
Research Grant